In our ongoing effort to enhance our customers’ experience, SCA Pharma has responded to feedback…
WINDSOR, CONN. (March 18, 2021)– Reflecting its unequivocal commitment to leading the 503B compounded pharmaceuticals outsourcing industry in excellence, SCA Pharmaceuticals has named Abby Kaplan as General Counsel and Chief Compliance Officer.
In what is a new C-suite role for SCA Pharma, Kaplan will handle all legal and regulatory affairs and plan and direct all of the company’s policies and practices to ensure that business units are complying with global, federal and local regulatory requirements.
“Quality has become the deal maker and breaker within the sterile compounding industry — which is exactly right, considering how critically important safe drugs are for the health and well-being of patients we serve,” said Milton Boyer, CEO. “Abby brings to SCA Pharma a long track record of compliance excellence at 503B facilities like ours, and I know her expertise will cement our standing as the quality leader within our field. I am excited that Abby has joined our team.”
Kaplan has more than 15 years of legal, regulatory and compliance experience in health care.
Previously, she served as executive vice president of administration at Avella Specialty Pharmacy, a billion-dollar enterprise with 503A and 503B facilities, where she managed the legal, compliance and human resources departments, and spearheaded acquisition and divestiture efforts, including diligence, deal negotiation, documentation and integration.
While at Avella, she served as president and a founding member of the Outsourcing Facility Association, a trade association of national 503B facilities.
Kaplan then transitioned to chief operating officer for OptumRx’s 503B line of business. In 2019, she left to serve as chief executive officer for a pre-clinical dermatology start-up and pursue her master’s degree in business administration from the University of Michigan.
“SCA Pharma is devoted to upholding the highest standards of legal and regulatory compliance to ensure the health and well-being of patients,” Kaplan said. “I am honored and excited to have the opportunity to work with the SCA Pharma team to further enhance its robust compliance program.”
Kaplan holds a bachelor’s degree with high distinction from the University of Michigan and earned her juris doctorate from Columbia University. She expects to receive her MBA degree with distinction in April.
SCA Pharma is executing an ambitious construction plan to expand its two sterile pharmaceutical manufacturing sites in Windsor, Conn., and Little Rock, Ark. The expansion will increase SCA Pharma’s physical footprint by 50 percent and introduce significant new automation to enhance scalability. The company recently announced that it had entered into a definitive membership interest purchase agreement with The Vistria Group and Excellere Partners.